Melbourne, Aug 21, 2008 (ABN Newswire) - Australian regenerative medicine company Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that its allogeneic, or “off-the-shelf”, cell therapy product was safe and highly effective in preclinical trials for interbody fusion of the cervical spine in the neck.
